Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective:The purpose of this article is to review the pharmacological characteristics and clinical evidence of oral semaglutide for the treatment of type 2 diabetes mellitus (T2DM). Data Sources: A MEDLINE/PubMed search was conducted between January 1, 2005, and September 30, 2019. Search terms included semaglutide, glucagon-like peptide 1 receptor agonist, GLP-1 receptor agonist, and type 2 diabetes. Study Selection and Data Extraction Quantification: The following study designs were included in the analysis: systematic review and/or meta-analyses, clinical trial, or observational study design. Narrative reviews were excluded. Articles were included only if they were published in the English language or evaluated oral semaglutide with regard to pharmacology, pharmacokinetics, safety, and efficacy in humans. Data Synthesis: Oral semaglutide has been Food and Drug Administration approved for the treatment of T2DM as an adjunct to diet and exercise. Oral semaglutide has been shown to result in an absolute hemoglobin A 1C reduction between −0.5% and −1.5% and weight reductions between −1 and −4.7 kg. Oral semaglutide has been shown to be noninferior to placebo for cardiovascular (CV) safety although additional CV outcomes trials are ongoing. Adverse effects appear to be similar to those of other glucagon-like peptide-1 receptor agonists and are gastrointestinal in nature. Relevance to Patient Care and Clinical Practice: Oral semaglutide may be appropriate as second- or third-line add-on therapy for patients with T2DM who are not meeting treatment goals on metformin and are overweight and reluctant to use an injectable drug. Conclusions: Oral semaglutide appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United States, oral and injectable forms of SMG are approved for treating T2DM, while only injectable forms are approved for treating obesity (103).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [103]
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · cited 5×
“Despite the rates of nausea observed in the PIONEER trials, only a small increase in discontinuation of oral semaglutide as compared with the active drug arms were found.(15,17,19) The largest discontinuation rates across the PIONEER trials occurred consistently with semaglutide 14 mg and were dose dependent.”
BackgroundResultInfluentialAroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Cefalu, W. T., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M. L., Morris, P. B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.020 · Cited by 300 · cited 1×
“To date, of the 5 FDA-approved GLP-1 RAs, liraglutide has the strongest evidence for reducing CV events and is the preferred GLP-1 RA in the 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for CV Risk Reduction in Patients with T2DM and ASCVD, and in the 2019 American Diabetes Association (ADA) Standards…”
BackgroundDavies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235 · cited 3×
“%) as compared with placebo (4%).19 As was demonstrated in PIONEER 5, and consistent with findings from the LIRA-RENAL trial, gastrointestinal events were more common in patients with stage 3A versus 3B CKD.22,27 Across the PIONEER program, more patients treated with oral semaglutide (~5% to 7”
ResultInfluential
Research works printed but not linked: 6
- American Diabetes Association, 2019, Standards of Medical Care in Diabetes—2019. Diabetes Care, 42, S90
- Baekdal TA, 2017, Diabetes, 66, A315
- 10.1007/s40262-019-00756–2 · DOI
- Baekdal T, Poster presented at: 54th Annual Meeting of the European Association for the Study of Diabetes;
- 10.1016/s2213-8587(19)30194–9 · DOI · Paper page
- 10.1007/s40262-018-0649–2 · DOI · Paper page
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
Ahmad, Y., Seo, D. S., & Jang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137076 · Cited by 49
“Semaglutide, a drug developed by Novo Nordisk, has significant therapeutic effects and is used in obesity treatment [76].”
BackgroundShao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Bækdal, T. A., Donsmark, M., Hartoft‐Nielsen, M., Søndergaard, F. L., & Connor, A. L. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.938 · Cited by 45
Metadata
- Authors
- Cowart, K.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Cowart, Kevin
- ORCID
- Cowart, Kevin
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2019-11-19
- Volume
- 54
- Issue
- 5
- Pages
- 478-485
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2989987822
- Cited by
- 42
- References
- 19
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 13 · 2023: 1 · 2022: 5 · 2021: 5 · 2020: 3
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, pharmacokinetics, glycemic control, HbA1c, weight loss, cardiovascular safety, gastrointestinal adverse effects, adjunctive therapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1177/1060028019889064
- The paper
- Cowart, K. (2020). Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028019889064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.